Expertise in
11
conditions

Dr. Ray Pais

Pediatrics
Childrens Hematology Oncology
2018 Clinch Ave # 2R2R, 
Knoxville, TN 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Expertise in
11
conditions
Childrens Hematology Oncology
2018 Clinch Ave # 2R2R, 
Knoxville, TN 

Overview

Ray Pais is a Pediatrics provider in Knoxville, Tennessee. Dr. Pais is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Hepatoblastoma, Rhabdoid Tumor, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

His clinical research consists of participating in 64 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatrics

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Childrens Hematology Oncology
2018 Clinch Ave # 2R2R, Knoxville, TN 37916

Additional Areas of Focus

Dr. Pais has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

63 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Other
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Expertise in
17
conditions
Dr. Jeffrey Schlactus
Pediatrics
Expertise in
17
conditions
Dr. Jeffrey Schlactus
Pediatrics

Allergy Associates PA

801 N Weisgarber Rd Ste 200, 
Knoxville, TN 
 (4.7 miles away)
865-584-8588
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Schlactus is a Pediatrics provider in Knoxville, Tennessee. Dr. Schlactus is highly rated in 17 conditions, according to our data. His top areas of expertise are Allergic Rhinitis, Sinusitis, Grass Allergy, and Angioedema.

Expertise in
18
conditions
Dr. Rhys Irvine
Pediatrics
Expertise in
18
conditions
Dr. Rhys Irvine
Pediatrics

Etch Pediatric Urology

2100 Clinch Ave Ste 310, 
Knoxville, TN 
 (0.3 miles away)
865-673-9315
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rhys Irvine is a Pediatrics provider in Knoxville, Tennessee. Dr. Irvine is highly rated in 18 conditions, according to our data. His top areas of expertise are Loin Pain Hematuria Syndrome, Testicular Torsion, Hypospadias, Bladder Reconstruction, and Ureteroscopy.

Expertise in
17
conditions
Dr. John Crawford
Pediatrics
Expertise in
17
conditions
Dr. John Crawford
Pediatrics

Orthotennessee PC

1422 Old Weisgarber Rd, 
Knoxville, TN 
 (4.6 miles away)
865-558-4400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Crawford is a Pediatrics provider in Knoxville, Tennessee. Dr. Crawford is highly rated in 17 conditions, according to our data. His top areas of expertise are Macrodactyly of the Foot, Freiberg's Disease, Accessory Navicular Bone, and Congenital Radioulnar Synostosis.

Frequently Asked Questions about Dr. Ray Pais

How do I make an appointment with Dr. Ray Pais?

You can book an appointment with Dr. Ray Pais by calling their office at 865-541-8266. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ray Pais a top-rated expert for Ewing Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ray Pais is classified as an Advanced expert for Ewing Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ray Pais specialize in?

While Dr. Ray Pais is a Pediatrics, they have specific expertise in Ewing Sarcoma, Hepatoblastoma, and Rhabdoid Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Ray Pais accept my insurance?

Dr. Ray Pais accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 865-541-8266 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pais's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile